Literature DB >> 35020824

The predictive value of a positive phase 2 ASH abstract for peer-reviewed publication and progression to phase 3.

David G J Cucchi1,2, Tobias B Polak3, Gert J Ossenkoppele1, Jacob M Rowe4, Elihu H Estey5.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35020824     DOI： 10.1182/blood.2021013988

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  1 in total

1.  Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020.

Authors:  Tobias B Polak; David GJ Cucchi; Jonathan J Darrow; Matthijs M Versteegh
Journal:  BMJ Open       Date:  2022-04-08       Impact factor: 2.692
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.